Coacervate-Filled Lipid Vesicles for Protein Delivery
© 2023 Wiley-VCH GmbH..
Macromolecularly crowded coacervate is useful in protein delivery for tissue engineering and regenerative medicine. However, coacervate tends to aggregate easily, which impedes their application. Here, this work presents a method to prepare coacervate with enhanced stability. This work assembles phospholipids on the surface of a coacervate to form lipocoacervate (LipCo). The resultant LipCo possesses a discrete spherical structure with a coacervate interior and phospholipid outer shell. The size of LipCo does not change over the four-week observation window, whereas coacervate coalesced into one bulk phase within 30 min. This work uses vascular endothelial growth factor-C (VEGF-C) and fibroblast growth factor-2 (FGF-2) as examples to test LipCo's ability to maintain protein bioactivity. The in vitro lymphangiogenesis assay demonstrates that human dermal lymphatic endothelial cells (LECs) formed increased network of cord in VEGF-C and FGF-2 loaded LipCo group compared to free proteins and proteins loaded in coacervate. Overall, LipCo could serve as a protein delivery vehicle with improved colloidal stability.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
Macromolecular bioscience - 23(2023), 6 vom: 20. Juni, Seite e2200538 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yeh, Chia-Wei [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 16.06.2023 Date Revised 20.06.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/mabi.202200538 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM352598867 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM352598867 | ||
| 003 | DE-627 | ||
| 005 | 20231226054108.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/mabi.202200538 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1175.xml |
| 035 | |a (DE-627)NLM352598867 | ||
| 035 | |a (NLM)36749955 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yeh, Chia-Wei |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Coacervate-Filled Lipid Vesicles for Protein Delivery |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.06.2023 | ||
| 500 | |a Date Revised 20.06.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 Wiley-VCH GmbH. | ||
| 520 | |a Macromolecularly crowded coacervate is useful in protein delivery for tissue engineering and regenerative medicine. However, coacervate tends to aggregate easily, which impedes their application. Here, this work presents a method to prepare coacervate with enhanced stability. This work assembles phospholipids on the surface of a coacervate to form lipocoacervate (LipCo). The resultant LipCo possesses a discrete spherical structure with a coacervate interior and phospholipid outer shell. The size of LipCo does not change over the four-week observation window, whereas coacervate coalesced into one bulk phase within 30 min. This work uses vascular endothelial growth factor-C (VEGF-C) and fibroblast growth factor-2 (FGF-2) as examples to test LipCo's ability to maintain protein bioactivity. The in vitro lymphangiogenesis assay demonstrates that human dermal lymphatic endothelial cells (LECs) formed increased network of cord in VEGF-C and FGF-2 loaded LipCo group compared to free proteins and proteins loaded in coacervate. Overall, LipCo could serve as a protein delivery vehicle with improved colloidal stability | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, U.S. Gov't, Non-P.H.S. | |
| 650 | 4 | |a FGF-2 | |
| 650 | 4 | |a VEGF-C | |
| 650 | 4 | |a coacervate | |
| 650 | 4 | |a growth factor | |
| 650 | 4 | |a heparin | |
| 650 | 4 | |a lipid vesicle | |
| 650 | 4 | |a lymphangiogenesis | |
| 650 | 4 | |a protein delivery | |
| 650 | 7 | |a Vascular Endothelial Growth Factor C |2 NLM | |
| 650 | 7 | |a Fibroblast Growth Factor 2 |2 NLM | |
| 650 | 7 | |a 103107-01-3 |2 NLM | |
| 650 | 7 | |a Lipids |2 NLM | |
| 700 | 1 | |a Wang, Yadong |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Macromolecular bioscience |d 2004 |g 23(2023), 6 vom: 20. Juni, Seite e2200538 |w (DE-627)NLM151409706 |x 1616-5195 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2023 |g number:6 |g day:20 |g month:06 |g pages:e2200538 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/mabi.202200538 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2023 |e 6 |b 20 |c 06 |h e2200538 | ||